C. Lowry Barnes
Concepts (609)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthroplasty, Replacement, Knee | 57 | 2024 | 288 | 12.430 |
Why?
| | Arthroplasty, Replacement, Hip | 52 | 2024 | 268 | 12.320 |
Why?
| | Antibodies, Neutralizing | 22 | 2025 | 79 | 4.350 |
Why?
| | Allergens | 7 | 2025 | 140 | 2.490 |
Why?
| | Antibodies, Viral | 14 | 2025 | 113 | 2.410 |
Why?
| | Orthopedics | 10 | 2022 | 53 | 2.370 |
Why?
| | Osteoarthritis, Knee | 11 | 2022 | 97 | 2.200 |
Why?
| | Humans | 166 | 2025 | 52441 | 2.080 |
Why?
| | Health Literacy | 5 | 2019 | 131 | 1.970 |
Why?
| | Length of Stay | 18 | 2024 | 673 | 1.930 |
Why?
| | Coronavirus Infections | 9 | 2021 | 188 | 1.830 |
Why?
| | Pneumonia, Viral | 8 | 2020 | 175 | 1.830 |
Why?
| | Air Pollution, Indoor | 5 | 2025 | 27 | 1.760 |
Why?
| | Reoperation | 13 | 2024 | 463 | 1.750 |
Why?
| | Knee Joint | 19 | 2023 | 165 | 1.740 |
Why?
| | Patient Readmission | 13 | 2024 | 249 | 1.710 |
Why?
| | Aged | 54 | 2024 | 10242 | 1.640 |
Why?
| | Arthroplasty, Replacement | 5 | 2019 | 27 | 1.640 |
Why?
| | Hip Prosthesis | 6 | 2021 | 73 | 1.630 |
Why?
| | Medicare | 17 | 2024 | 281 | 1.620 |
Why?
| | Analgesics, Opioid | 10 | 2024 | 601 | 1.610 |
Why?
| | Preoperative Care | 5 | 2018 | 173 | 1.550 |
Why?
| | Epitopes | 12 | 2025 | 62 | 1.460 |
Why?
| | Retrospective Studies | 43 | 2024 | 6694 | 1.450 |
Why?
| | Hypersensitivity | 6 | 2018 | 80 | 1.370 |
Why?
| | United States | 30 | 2024 | 5215 | 1.350 |
Why?
| | Pandemics | 12 | 2022 | 580 | 1.340 |
Why?
| | Fungi | 4 | 2025 | 51 | 1.300 |
Why?
| | Periprosthetic Fractures | 4 | 2022 | 11 | 1.270 |
Why?
| | Postoperative Complications | 13 | 2024 | 1065 | 1.210 |
Why?
| | Pain, Postoperative | 7 | 2024 | 169 | 1.200 |
Why?
| | Prosthesis-Related Infections | 6 | 2023 | 108 | 1.180 |
Why?
| | Range of Motion, Articular | 8 | 2022 | 110 | 1.170 |
Why?
| | Joint Diseases | 3 | 2018 | 39 | 1.160 |
Why?
| | HIV Antibodies | 6 | 2022 | 15 | 1.150 |
Why?
| | HIV-1 | 8 | 2022 | 60 | 1.140 |
Why?
| | Critical Pathways | 3 | 2017 | 36 | 1.120 |
Why?
| | Patient Discharge | 14 | 2022 | 320 | 1.120 |
Why?
| | Golf | 3 | 2023 | 9 | 1.120 |
Why?
| | env Gene Products, Human Immunodeficiency Virus | 5 | 2022 | 5 | 1.120 |
Why?
| | Hip Dislocation | 2 | 2019 | 17 | 1.090 |
Why?
| | Orthopedic Procedures | 6 | 2020 | 70 | 1.080 |
Why?
| | Patient Education as Topic | 5 | 2018 | 317 | 1.050 |
Why?
| | Comprehension | 2 | 2018 | 114 | 1.020 |
Why?
| | Middle Aged | 40 | 2024 | 13133 | 0.970 |
Why?
| | Male | 57 | 2024 | 26874 | 0.970 |
Why?
| | Respiratory Tract Diseases | 2 | 2018 | 29 | 0.960 |
Why?
| | Antibodies, Bispecific | 2 | 2025 | 104 | 0.950 |
Why?
| | Female | 56 | 2025 | 28277 | 0.930 |
Why?
| | HIV Envelope Protein gp120 | 4 | 2020 | 13 | 0.920 |
Why?
| | Prosthesis Failure | 5 | 2020 | 112 | 0.920 |
Why?
| | Climate Change | 2 | 2018 | 56 | 0.920 |
Why?
| | Respiratory Hypersensitivity | 1 | 2025 | 17 | 0.910 |
Why?
| | Immunoglobulin G | 5 | 2021 | 193 | 0.910 |
Why?
| | Antigens, Fungal | 1 | 2025 | 19 | 0.910 |
Why?
| | Osteoarthritis | 6 | 2023 | 63 | 0.870 |
Why?
| | Joint Instability | 2 | 2022 | 43 | 0.870 |
Why?
| | Risk Factors | 18 | 2023 | 3971 | 0.860 |
Why?
| | Pain Management | 3 | 2016 | 187 | 0.850 |
Why?
| | Pollen | 3 | 2018 | 5 | 0.830 |
Why?
| | Hip | 2 | 2020 | 23 | 0.790 |
Why?
| | Anthozoa | 1 | 2022 | 6 | 0.780 |
Why?
| | Cryoelectron Microscopy | 8 | 2025 | 15 | 0.780 |
Why?
| | Diterpenes | 1 | 2022 | 26 | 0.770 |
Why?
| | Leadership | 2 | 2020 | 105 | 0.760 |
Why?
| | Lordosis | 1 | 2022 | 4 | 0.760 |
Why?
| | Polysaccharides | 6 | 2022 | 58 | 0.760 |
Why?
| | Prosthesis Design | 4 | 2021 | 262 | 0.750 |
Why?
| | Opioid-Related Disorders | 5 | 2023 | 404 | 0.750 |
Why?
| | Kyphosis | 1 | 2022 | 14 | 0.750 |
Why?
| | Hospitals | 10 | 2024 | 182 | 0.750 |
Why?
| | Housing | 4 | 2016 | 48 | 0.740 |
Why?
| | HIV Infections | 6 | 2022 | 394 | 0.730 |
Why?
| | Knee | 3 | 2021 | 25 | 0.730 |
Why?
| | Sleep | 4 | 2025 | 191 | 0.720 |
Why?
| | Mycobacterium tuberculosis | 1 | 2022 | 245 | 0.700 |
Why?
| | Blood Transfusion | 3 | 2016 | 126 | 0.690 |
Why?
| | Transurethral Resection of Prostate | 1 | 2021 | 10 | 0.690 |
Why?
| | Prostatic Hyperplasia | 1 | 2021 | 39 | 0.670 |
Why?
| | Dust | 3 | 2019 | 24 | 0.670 |
Why?
| | Knee Prosthesis | 4 | 2023 | 51 | 0.660 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2020 | 19 | 0.660 |
Why?
| | Animals | 26 | 2025 | 13485 | 0.650 |
Why?
| | Work | 1 | 2020 | 11 | 0.650 |
Why?
| | Antibodies, Monoclonal | 12 | 2025 | 475 | 0.630 |
Why?
| | Asthma | 4 | 2017 | 313 | 0.620 |
Why?
| | Disease Susceptibility | 1 | 2019 | 97 | 0.620 |
Why?
| | Aged, 80 and over | 13 | 2024 | 3449 | 0.610 |
Why?
| | Environment | 1 | 2019 | 88 | 0.610 |
Why?
| | Anesthesia, General | 4 | 2024 | 99 | 0.610 |
Why?
| | Interprofessional Relations | 1 | 2020 | 91 | 0.600 |
Why?
| | Surgery Department, Hospital | 1 | 2019 | 4 | 0.600 |
Why?
| | Bone Cements | 1 | 2019 | 30 | 0.600 |
Why?
| | Polymethyl Methacrylate | 1 | 2019 | 26 | 0.590 |
Why?
| | Societies, Medical | 2 | 2020 | 200 | 0.590 |
Why?
| | Hip Joint | 2 | 2020 | 55 | 0.590 |
Why?
| | Food Hypersensitivity | 1 | 2019 | 100 | 0.580 |
Why?
| | Diabetic Foot | 1 | 2019 | 78 | 0.570 |
Why?
| | Cost Savings | 2 | 2017 | 60 | 0.570 |
Why?
| | Comorbidity | 5 | 2018 | 637 | 0.560 |
Why?
| | Models, Molecular | 9 | 2021 | 356 | 0.560 |
Why?
| | Arthroplasty | 4 | 2023 | 26 | 0.560 |
Why?
| | Yoga | 1 | 2018 | 15 | 0.550 |
Why?
| | Hospitals, Teaching | 2 | 2019 | 52 | 0.540 |
Why?
| | Protein Binding | 9 | 2024 | 673 | 0.530 |
Why?
| | Environmental Exposure | 5 | 2025 | 225 | 0.530 |
Why?
| | Inpatients | 7 | 2020 | 203 | 0.530 |
Why?
| | Clinical Protocols | 1 | 2017 | 106 | 0.520 |
Why?
| | Postoperative Period | 6 | 2018 | 169 | 0.520 |
Why?
| | Quadriceps Muscle | 4 | 2022 | 47 | 0.510 |
Why?
| | Arthritis, Infectious | 3 | 2023 | 43 | 0.510 |
Why?
| | AIDS Vaccines | 3 | 2021 | 11 | 0.510 |
Why?
| | Patient Navigation | 1 | 2016 | 13 | 0.510 |
Why?
| | B-Lymphocytes | 7 | 2024 | 178 | 0.510 |
Why?
| | Antifibrinolytic Agents | 1 | 2016 | 15 | 0.500 |
Why?
| | Binding Sites | 6 | 2024 | 379 | 0.500 |
Why?
| | Tranexamic Acid | 1 | 2016 | 14 | 0.490 |
Why?
| | Early Ambulation | 1 | 2016 | 5 | 0.490 |
Why?
| | Anti-Bacterial Agents | 4 | 2023 | 816 | 0.490 |
Why?
| | Adult | 25 | 2024 | 14205 | 0.480 |
Why?
| | Musculoskeletal Pain | 1 | 2016 | 10 | 0.480 |
Why?
| | Caregivers | 1 | 2018 | 239 | 0.480 |
Why?
| | Quality of Health Care | 1 | 2017 | 186 | 0.470 |
Why?
| | Publishing | 1 | 2016 | 42 | 0.470 |
Why?
| | Periodicals as Topic | 1 | 2016 | 63 | 0.450 |
Why?
| | Analgesia, Epidural | 1 | 2015 | 28 | 0.450 |
Why?
| | Public Opinion | 3 | 2025 | 22 | 0.450 |
Why?
| | Bupivacaine | 1 | 2015 | 29 | 0.440 |
Why?
| | Narcotics | 3 | 2020 | 109 | 0.430 |
Why?
| | Cross-Sectional Studies | 7 | 2020 | 1677 | 0.430 |
Why?
| | Intermittent Pneumatic Compression Devices | 1 | 2014 | 2 | 0.430 |
Why?
| | Air Pollutants | 2 | 2013 | 78 | 0.420 |
Why?
| | Epilepsy | 1 | 2016 | 191 | 0.410 |
Why?
| | Treatment Outcome | 10 | 2024 | 5508 | 0.410 |
Why?
| | Exercise | 1 | 2018 | 559 | 0.410 |
Why?
| | Venous Thromboembolism | 1 | 2014 | 80 | 0.390 |
Why?
| | Cross Reactions | 3 | 2021 | 43 | 0.390 |
Why?
| | DNA Methylation | 1 | 2016 | 573 | 0.380 |
Why?
| | Mutation | 7 | 2021 | 1331 | 0.370 |
Why?
| | Activities of Daily Living | 3 | 2023 | 185 | 0.370 |
Why?
| | Health Expenditures | 3 | 2017 | 74 | 0.370 |
Why?
| | Work Schedule Tolerance | 2 | 2021 | 5 | 0.360 |
Why?
| | Sleep Disorders, Circadian Rhythm | 2 | 2021 | 5 | 0.360 |
Why?
| | Mice | 13 | 2025 | 5899 | 0.360 |
Why?
| | Osteonecrosis | 2 | 2022 | 35 | 0.350 |
Why?
| | Receptors, Virus | 2 | 2021 | 26 | 0.350 |
Why?
| | Lower Extremity | 3 | 2023 | 97 | 0.330 |
Why?
| | Crystallography, X-Ray | 4 | 2021 | 158 | 0.320 |
Why?
| | Odds Ratio | 5 | 2019 | 563 | 0.320 |
Why?
| | Pain | 4 | 2024 | 373 | 0.320 |
Why?
| | Acetabulum | 3 | 2020 | 39 | 0.310 |
Why?
| | Neutralization Tests | 7 | 2023 | 28 | 0.310 |
Why?
| | Young Adult | 10 | 2021 | 4346 | 0.310 |
Why?
| | Tibial Fractures | 2 | 2021 | 33 | 0.300 |
Why?
| | Cost-Benefit Analysis | 3 | 2021 | 271 | 0.300 |
Why?
| | Osteoarthritis, Hip | 3 | 2019 | 28 | 0.300 |
Why?
| | Fee-for-Service Plans | 2 | 2020 | 18 | 0.290 |
Why?
| | Movement | 4 | 2021 | 83 | 0.280 |
Why?
| | Nanoparticles | 3 | 2021 | 131 | 0.280 |
Why?
| | Crystallization | 3 | 2016 | 34 | 0.270 |
Why?
| | Patient Satisfaction | 2 | 2020 | 287 | 0.270 |
Why?
| | Viscosupplements | 2 | 2017 | 14 | 0.270 |
Why?
| | Hyaluronic Acid | 2 | 2017 | 38 | 0.260 |
Why?
| | Antibody Affinity | 3 | 2021 | 9 | 0.260 |
Why?
| | Mice, Inbred BALB C | 2 | 2025 | 304 | 0.260 |
Why?
| | Adolescent | 10 | 2021 | 6713 | 0.250 |
Why?
| | Recombinant Proteins | 2 | 2020 | 490 | 0.250 |
Why?
| | Indians, North American | 2 | 2018 | 36 | 0.250 |
Why?
| | Risk | 2 | 2017 | 315 | 0.240 |
Why?
| | HEK293 Cells | 4 | 2020 | 236 | 0.240 |
Why?
| | Smoking | 3 | 2018 | 514 | 0.240 |
Why?
| | Policy Making | 1 | 2025 | 35 | 0.240 |
Why?
| | Microscopy, Electron, Transmission | 2 | 2016 | 68 | 0.230 |
Why?
| | Logistic Models | 3 | 2016 | 930 | 0.230 |
Why?
| | Spores, Fungal | 1 | 2025 | 20 | 0.230 |
Why?
| | Muscle Strength | 3 | 2022 | 132 | 0.230 |
Why?
| | Symbiosis | 1 | 2024 | 12 | 0.230 |
Why?
| | Staphylococcus epidermidis | 1 | 2024 | 16 | 0.220 |
Why?
| | Antibodies, Bacterial | 1 | 2024 | 29 | 0.220 |
Why?
| | Reproducibility of Results | 4 | 2022 | 1223 | 0.220 |
Why?
| | RNA Polymerase II | 1 | 2024 | 14 | 0.220 |
Why?
| | Magnesium | 1 | 2024 | 35 | 0.220 |
Why?
| | Catalytic Domain | 1 | 2024 | 61 | 0.220 |
Why?
| | Hip Fractures | 2 | 2023 | 48 | 0.220 |
Why?
| | Molecular Dynamics Simulation | 1 | 2024 | 44 | 0.220 |
Why?
| | Poverty | 2 | 2016 | 218 | 0.220 |
Why?
| | Arthralgia | 3 | 2022 | 44 | 0.220 |
Why?
| | Cricetulus | 3 | 2020 | 100 | 0.220 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 71 | 0.210 |
Why?
| | CHO Cells | 3 | 2020 | 123 | 0.210 |
Why?
| | Delivery of Health Care | 2 | 2017 | 317 | 0.210 |
Why?
| | Protein Multimerization | 3 | 2021 | 57 | 0.210 |
Why?
| | Meteorological Concepts | 1 | 2003 | 2 | 0.210 |
Why?
| | Spores | 1 | 2003 | 2 | 0.210 |
Why?
| | Hospital Mortality | 2 | 2016 | 451 | 0.210 |
Why?
| | Information Services | 1 | 2003 | 13 | 0.210 |
Why?
| | Femur | 2 | 2021 | 132 | 0.210 |
Why?
| | Antibiotic Prophylaxis | 1 | 2023 | 63 | 0.200 |
Why?
| | Host-Pathogen Interactions | 2 | 2021 | 130 | 0.200 |
Why?
| | Knee Injuries | 1 | 2023 | 29 | 0.200 |
Why?
| | Transcription, Genetic | 1 | 2024 | 375 | 0.200 |
Why?
| | Caribbean Region | 1 | 2022 | 5 | 0.200 |
Why?
| | Femoral Fractures | 1 | 2023 | 40 | 0.190 |
Why?
| | Mechanotransduction, Cellular | 1 | 2023 | 41 | 0.190 |
Why?
| | Macaca mulatta | 2 | 2020 | 94 | 0.190 |
Why?
| | Bone Neoplasms | 1 | 2024 | 188 | 0.190 |
Why?
| | Braces | 1 | 2002 | 9 | 0.190 |
Why?
| | Bone Diseases, Metabolic | 1 | 2023 | 80 | 0.190 |
Why?
| | Proteins | 2 | 2016 | 353 | 0.190 |
Why?
| | Gait | 2 | 2021 | 88 | 0.190 |
Why?
| | Myositis | 1 | 2022 | 20 | 0.180 |
Why?
| | Outpatients | 2 | 2020 | 128 | 0.180 |
Why?
| | Pain Measurement | 3 | 2019 | 263 | 0.180 |
Why?
| | Pelvis | 1 | 2022 | 65 | 0.180 |
Why?
| | Osteocytes | 1 | 2024 | 219 | 0.180 |
Why?
| | Molecular Structure | 1 | 2022 | 317 | 0.180 |
Why?
| | Protein Interaction Domains and Motifs | 1 | 2021 | 21 | 0.180 |
Why?
| | Critical Illness | 2 | 2021 | 306 | 0.180 |
Why?
| | Cricetinae | 2 | 2020 | 189 | 0.180 |
Why?
| | Injections, Intra-Articular | 3 | 2017 | 38 | 0.180 |
Why?
| | Skin | 1 | 2024 | 416 | 0.180 |
Why?
| | Sepsis | 2 | 2021 | 236 | 0.180 |
Why?
| | Metal-on-Metal Joint Prostheses | 1 | 2021 | 5 | 0.180 |
Why?
| | Databases, Factual | 4 | 2019 | 721 | 0.180 |
Why?
| | Cost of Illness | 1 | 2022 | 120 | 0.180 |
Why?
| | Multiple Myeloma | 1 | 2016 | 3013 | 0.180 |
Why?
| | Anemia, Sickle Cell | 1 | 2022 | 101 | 0.180 |
Why?
| | Lumbar Vertebrae | 1 | 2022 | 99 | 0.180 |
Why?
| | Glycosylation | 2 | 2019 | 104 | 0.180 |
Why?
| | Radiography | 5 | 2019 | 469 | 0.170 |
Why?
| | Protein Engineering | 2 | 2020 | 18 | 0.170 |
Why?
| | Vaccines, Synthetic | 1 | 2021 | 21 | 0.170 |
Why?
| | Crowdsourcing | 1 | 2021 | 10 | 0.170 |
Why?
| | Immunity, Humoral | 1 | 2021 | 23 | 0.170 |
Why?
| | Molecular Biology | 1 | 2021 | 27 | 0.170 |
Why?
| | Posture | 1 | 2021 | 66 | 0.170 |
Why?
| | Vaccination | 2 | 2022 | 294 | 0.170 |
Why?
| | Joints | 2 | 2018 | 19 | 0.170 |
Why?
| | Femur Head Necrosis | 1 | 2020 | 17 | 0.170 |
Why?
| | Intubation, Intratracheal | 1 | 2021 | 116 | 0.170 |
Why?
| | Protein Conformation | 4 | 2024 | 178 | 0.170 |
Why?
| | Decompression, Surgical | 1 | 2020 | 48 | 0.170 |
Why?
| | Epitope Mapping | 1 | 2020 | 6 | 0.170 |
Why?
| | Hydrocortisone | 1 | 2021 | 112 | 0.170 |
Why?
| | Dissociative Disorders | 1 | 2020 | 10 | 0.170 |
Why?
| | Immunization, Passive | 1 | 2020 | 28 | 0.170 |
Why?
| | Polyethylene | 1 | 2020 | 18 | 0.160 |
Why?
| | Bariatric Surgery | 1 | 2021 | 44 | 0.160 |
Why?
| | Politics | 1 | 2020 | 29 | 0.160 |
Why?
| | Italy | 1 | 2020 | 27 | 0.160 |
Why?
| | Adrenal Cortex Hormones | 2 | 2020 | 116 | 0.160 |
Why?
| | Diagnosis-Related Groups | 2 | 2017 | 18 | 0.160 |
Why?
| | Obesity, Morbid | 1 | 2021 | 86 | 0.160 |
Why?
| | Peptide Fragments | 1 | 2020 | 214 | 0.160 |
Why?
| | Foot Orthoses | 1 | 2019 | 7 | 0.160 |
Why?
| | External Fixators | 1 | 2019 | 10 | 0.160 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2021 | 145 | 0.150 |
Why?
| | Costs and Cost Analysis | 2 | 2017 | 94 | 0.150 |
Why?
| | Viral Proteins | 1 | 2021 | 164 | 0.150 |
Why?
| | Clone Cells | 1 | 2019 | 76 | 0.150 |
Why?
| | Fracture Healing | 2 | 1996 | 28 | 0.150 |
Why?
| | Tobramycin | 1 | 2019 | 16 | 0.150 |
Why?
| | Hematologic Neoplasms | 1 | 2020 | 101 | 0.150 |
Why?
| | Antiviral Agents | 1 | 2020 | 173 | 0.150 |
Why?
| | After-Hours Care | 1 | 2019 | 12 | 0.150 |
Why?
| | Maternal Exposure | 1 | 2019 | 96 | 0.150 |
Why?
| | Models, Neurological | 1 | 2019 | 57 | 0.150 |
Why?
| | Systems Biology | 1 | 2019 | 33 | 0.150 |
Why?
| | Prostheses and Implants | 1 | 2019 | 53 | 0.150 |
Why?
| | HIV Envelope Protein gp41 | 1 | 2018 | 5 | 0.150 |
Why?
| | Bayes Theorem | 1 | 2019 | 122 | 0.150 |
Why?
| | Hospitals, University | 1 | 2019 | 73 | 0.150 |
Why?
| | Postural Balance | 2 | 2021 | 59 | 0.150 |
Why?
| | Gardening | 1 | 2018 | 2 | 0.150 |
Why?
| | Virus Internalization | 1 | 2018 | 20 | 0.150 |
Why?
| | Healthcare Disparities | 1 | 2022 | 291 | 0.140 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2019 | 52 | 0.140 |
Why?
| | Plants | 1 | 2018 | 28 | 0.140 |
Why?
| | Rural Population | 1 | 2023 | 587 | 0.140 |
Why?
| | Vancomycin | 1 | 2019 | 90 | 0.140 |
Why?
| | Immunoglobulin A | 3 | 2024 | 46 | 0.140 |
Why?
| | Exercise Test | 1 | 2019 | 134 | 0.140 |
Why?
| | Sulfhydryl Compounds | 1 | 2018 | 17 | 0.140 |
Why?
| | Radioisotopes | 1 | 2018 | 16 | 0.140 |
Why?
| | Medicaid | 2 | 2022 | 264 | 0.140 |
Why?
| | Multiple Sclerosis | 1 | 2019 | 72 | 0.140 |
Why?
| | Recreation | 1 | 2018 | 21 | 0.140 |
Why?
| | Rotation | 1 | 2018 | 45 | 0.140 |
Why?
| | Arsenic | 1 | 2018 | 22 | 0.140 |
Why?
| | Smoke-Free Policy | 1 | 2018 | 10 | 0.140 |
Why?
| | Microbial Sensitivity Tests | 1 | 2019 | 271 | 0.140 |
Why?
| | Infant, Premature | 1 | 2021 | 327 | 0.140 |
Why?
| | Drug Prescriptions | 1 | 2019 | 112 | 0.140 |
Why?
| | Cell Line | 1 | 2020 | 1020 | 0.140 |
Why?
| | Tramadol | 1 | 2018 | 30 | 0.140 |
Why?
| | Benzodiazepines | 1 | 2018 | 71 | 0.140 |
Why?
| | Guidelines as Topic | 1 | 2018 | 111 | 0.140 |
Why?
| | Child, Preschool | 6 | 2016 | 4046 | 0.130 |
Why?
| | Breast Feeding | 1 | 2019 | 201 | 0.130 |
Why?
| | Body Mass Index | 2 | 2018 | 701 | 0.130 |
Why?
| | Child | 8 | 2020 | 7194 | 0.130 |
Why?
| | Incidence | 3 | 2019 | 1096 | 0.130 |
Why?
| | Subacute Care | 1 | 2017 | 5 | 0.130 |
Why?
| | Recovery of Function | 1 | 2018 | 201 | 0.130 |
Why?
| | Risk Assessment | 2 | 2019 | 1349 | 0.130 |
Why?
| | Academic Medical Centers | 1 | 2018 | 151 | 0.130 |
Why?
| | Early Medical Intervention | 1 | 2017 | 14 | 0.130 |
Why?
| | Neurotransmitter Agents | 1 | 2017 | 33 | 0.130 |
Why?
| | Optical Imaging | 1 | 2017 | 25 | 0.130 |
Why?
| | Kansas | 1 | 2016 | 8 | 0.130 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2017 | 29 | 0.130 |
Why?
| | Reimbursement Mechanisms | 1 | 2017 | 24 | 0.130 |
Why?
| | Immunologic Memory | 3 | 2021 | 31 | 0.130 |
Why?
| | Dietary Proteins | 1 | 2019 | 247 | 0.130 |
Why?
| | Language | 1 | 2018 | 142 | 0.130 |
Why?
| | Patient Safety | 1 | 2017 | 102 | 0.130 |
Why?
| | Fractures, Bone | 4 | 1992 | 105 | 0.130 |
Why?
| | Nut Hypersensitivity | 1 | 2016 | 3 | 0.130 |
Why?
| | Cocos | 1 | 2016 | 3 | 0.130 |
Why?
| | Fractures, Open | 1 | 1996 | 8 | 0.130 |
Why?
| | Football | 1 | 2018 | 75 | 0.130 |
Why?
| | Fluorescent Dyes | 1 | 2017 | 91 | 0.130 |
Why?
| | Nuts | 1 | 2016 | 8 | 0.130 |
Why?
| | Time Factors | 5 | 2021 | 2987 | 0.130 |
Why?
| | Zinc | 1 | 2017 | 57 | 0.130 |
Why?
| | Hospitals, Community | 1 | 2016 | 19 | 0.120 |
Why?
| | Glutamic Acid | 1 | 2017 | 111 | 0.120 |
Why?
| | Transforming Growth Factor beta | 1 | 2017 | 136 | 0.120 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2021 | 234 | 0.120 |
Why?
| | Social Class | 1 | 2016 | 97 | 0.120 |
Why?
| | Social Support | 1 | 2018 | 270 | 0.120 |
Why?
| | Positron-Emission Tomography | 1 | 2018 | 297 | 0.120 |
Why?
| | Quality Improvement | 1 | 2018 | 226 | 0.120 |
Why?
| | Anesthesia, Spinal | 1 | 2016 | 17 | 0.120 |
Why?
| | Peer Review, Research | 1 | 2016 | 14 | 0.120 |
Why?
| | Anesthesia, Conduction | 1 | 2016 | 15 | 0.120 |
Why?
| | Anemia | 1 | 2016 | 75 | 0.120 |
Why?
| | Breast Neoplasms | 1 | 2024 | 1203 | 0.120 |
Why?
| | Congresses as Topic | 1 | 2016 | 49 | 0.120 |
Why?
| | Prescription Drug Misuse | 1 | 2016 | 31 | 0.120 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 58 | 0.120 |
Why?
| | Hemoglobins | 1 | 2016 | 114 | 0.120 |
Why?
| | Hyperalgesia | 1 | 2016 | 55 | 0.120 |
Why?
| | Chronic Disease | 1 | 2018 | 579 | 0.120 |
Why?
| | Pneumonia | 1 | 2016 | 122 | 0.120 |
Why?
| | Ambulatory Care Facilities | 1 | 2016 | 122 | 0.120 |
Why?
| | Environmental Health | 1 | 2015 | 14 | 0.110 |
Why?
| | Injections, Epidural | 1 | 2015 | 10 | 0.110 |
Why?
| | Liposomes | 1 | 2015 | 53 | 0.110 |
Why?
| | Arthroplasty, Replacement, Ankle | 1 | 2014 | 3 | 0.110 |
Why?
| | Multivariate Analysis | 1 | 2016 | 601 | 0.110 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 123 | 0.110 |
Why?
| | Follow-Up Studies | 3 | 2020 | 2294 | 0.110 |
Why?
| | Cohort Studies | 4 | 2021 | 1576 | 0.110 |
Why?
| | Age Factors | 1 | 2017 | 1120 | 0.110 |
Why?
| | Anesthetics, Local | 1 | 2015 | 77 | 0.110 |
Why?
| | Phylogeny | 3 | 2021 | 229 | 0.100 |
Why?
| | Bacteria | 1 | 2015 | 223 | 0.100 |
Why?
| | Drug Overdose | 1 | 2016 | 161 | 0.100 |
Why?
| | Socioeconomic Factors | 3 | 2023 | 609 | 0.100 |
Why?
| | Kinetics | 3 | 2021 | 613 | 0.100 |
Why?
| | Diabetes Mellitus | 1 | 2017 | 318 | 0.100 |
Why?
| | Arthropod Proteins | 1 | 2013 | 2 | 0.100 |
Why?
| | Antigens, Dermatophagoides | 1 | 2013 | 4 | 0.100 |
Why?
| | Severity of Illness Index | 1 | 2016 | 1045 | 0.100 |
Why?
| | Humeral Fractures | 1 | 1992 | 8 | 0.100 |
Why?
| | Cysteine Endopeptidases | 1 | 2013 | 65 | 0.100 |
Why?
| | Pulmonary Embolism | 1 | 2014 | 81 | 0.100 |
Why?
| | Joint Prosthesis | 1 | 1992 | 12 | 0.100 |
Why?
| | Venous Thrombosis | 1 | 2014 | 89 | 0.100 |
Why?
| | Patient Positioning | 1 | 2013 | 31 | 0.100 |
Why?
| | Mass Screening | 1 | 2016 | 354 | 0.100 |
Why?
| | Environmental Monitoring | 1 | 2013 | 76 | 0.100 |
Why?
| | Carpal Bones | 1 | 1992 | 2 | 0.100 |
Why?
| | Synostosis | 1 | 1992 | 2 | 0.100 |
Why?
| | Shoulder Joint | 1 | 1992 | 39 | 0.100 |
Why?
| | Glycoproteins | 1 | 2013 | 123 | 0.100 |
Why?
| | Diseases in Twins | 1 | 1992 | 13 | 0.090 |
Why?
| | Health Promotion | 1 | 2015 | 271 | 0.090 |
Why?
| | Ambulatory Care | 1 | 2014 | 238 | 0.090 |
Why?
| | Fungal Proteins | 1 | 2013 | 114 | 0.090 |
Why?
| | Tibia | 2 | 2023 | 113 | 0.090 |
Why?
| | Arm Injuries | 1 | 1991 | 10 | 0.090 |
Why?
| | Acute Kidney Injury | 1 | 2016 | 389 | 0.090 |
Why?
| | Lidocaine | 1 | 1991 | 48 | 0.090 |
Why?
| | Immune Evasion | 2 | 2021 | 15 | 0.090 |
Why?
| | Immunoglobulin E | 2 | 2016 | 92 | 0.090 |
Why?
| | Epitopes, B-Lymphocyte | 2 | 2021 | 4 | 0.090 |
Why?
| | Aging | 1 | 1996 | 722 | 0.090 |
Why?
| | Stroke | 1 | 2016 | 527 | 0.090 |
Why?
| | Nerve Block | 1 | 1991 | 42 | 0.090 |
Why?
| | Immunization | 2 | 2021 | 69 | 0.090 |
Why?
| | Antigens, Viral | 2 | 2021 | 44 | 0.090 |
Why?
| | Electrons | 2 | 2024 | 20 | 0.090 |
Why?
| | Mental Disorders | 1 | 2016 | 427 | 0.090 |
Why?
| | Osteoclasts | 2 | 2024 | 423 | 0.090 |
Why?
| | Lasers | 2 | 2024 | 64 | 0.090 |
Why?
| | Brain | 1 | 2019 | 1337 | 0.080 |
Why?
| | Fatigue | 2 | 2021 | 126 | 0.080 |
Why?
| | Immunoglobulin M | 2 | 2021 | 59 | 0.080 |
Why?
| | Viral Vaccines | 2 | 2021 | 16 | 0.080 |
Why?
| | Antigen-Antibody Complex | 2 | 2021 | 35 | 0.080 |
Why?
| | Somatic Hypermutation, Immunoglobulin | 2 | 2021 | 6 | 0.080 |
Why?
| | Signal Transduction | 1 | 2017 | 1724 | 0.080 |
Why?
| | Antibody Specificity | 2 | 2020 | 36 | 0.080 |
Why?
| | Obesity | 1 | 2017 | 1176 | 0.070 |
Why?
| | Molecular Conformation | 2 | 2018 | 67 | 0.070 |
Why?
| | Amino Acid Sequence | 2 | 2019 | 576 | 0.070 |
Why?
| | Gene Expression Profiling | 2 | 2024 | 1099 | 0.070 |
Why?
| | Mice, Inbred C57BL | 2 | 2024 | 1888 | 0.070 |
Why?
| | Muscle, Skeletal | 2 | 2022 | 799 | 0.060 |
Why?
| | Propensity Score | 2 | 2017 | 160 | 0.060 |
Why?
| | Quality of Life | 2 | 2022 | 893 | 0.060 |
Why?
| | Inflammation | 2 | 2022 | 649 | 0.060 |
Why?
| | Air | 1 | 2005 | 22 | 0.060 |
Why?
| | Hospitalization | 2 | 2020 | 731 | 0.060 |
Why?
| | Polyethylenes | 2 | 2023 | 14 | 0.060 |
Why?
| | Tetanus Toxin | 1 | 2024 | 2 | 0.060 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 498 | 0.060 |
Why?
| | Antibody Formation | 1 | 2024 | 51 | 0.060 |
Why?
| | Prospective Payment System | 1 | 2024 | 6 | 0.050 |
Why?
| | 5-Methoxytryptamine | 1 | 1994 | 1 | 0.050 |
Why?
| | Hydroxyindoleacetic Acid | 1 | 1994 | 8 | 0.050 |
Why?
| | Embryonic and Fetal Development | 1 | 1994 | 22 | 0.050 |
Why?
| | Blastocyst | 1 | 1994 | 15 | 0.050 |
Why?
| | Abnormalities, Drug-Induced | 1 | 1994 | 18 | 0.050 |
Why?
| | Melatonin | 1 | 1994 | 17 | 0.050 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 140 | 0.050 |
Why?
| | Fetal Diseases | 1 | 1994 | 54 | 0.050 |
Why?
| | Health Status | 1 | 2005 | 300 | 0.050 |
Why?
| | Quality Indicators, Health Care | 1 | 2024 | 91 | 0.050 |
Why?
| | Adenosine Triphosphate | 1 | 2024 | 234 | 0.050 |
Why?
| | Particle Size | 1 | 2003 | 76 | 0.050 |
Why?
| | Arkansas | 2 | 2019 | 2013 | 0.050 |
Why?
| | Algorithms | 2 | 2019 | 673 | 0.050 |
Why?
| | International Classification of Diseases | 1 | 2023 | 70 | 0.050 |
Why?
| | Aerosols | 1 | 2003 | 74 | 0.050 |
Why?
| | Tertiary Care Centers | 1 | 2023 | 83 | 0.050 |
Why?
| | Germ Cells | 1 | 2022 | 14 | 0.050 |
Why?
| | Transplantation, Homologous | 1 | 2023 | 151 | 0.050 |
Why?
| | Ion Channels | 1 | 2023 | 74 | 0.050 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 257 | 0.050 |
Why?
| | Administration, Oral | 1 | 2023 | 455 | 0.050 |
Why?
| | Health Status Indicators | 1 | 2002 | 81 | 0.050 |
Why?
| | Antibodies, Heterophile | 1 | 2021 | 1 | 0.050 |
Why?
| | Macaca | 1 | 2021 | 9 | 0.050 |
Why?
| | Transcriptome | 1 | 2024 | 357 | 0.050 |
Why?
| | Benchmarking | 1 | 2022 | 64 | 0.050 |
Why?
| | Muscles | 1 | 2022 | 108 | 0.040 |
Why?
| | Bacterial Proteins | 1 | 2024 | 347 | 0.040 |
Why?
| | New York | 1 | 2021 | 51 | 0.040 |
Why?
| | Femur Neck | 1 | 2021 | 6 | 0.040 |
Why?
| | Chromium | 1 | 2021 | 5 | 0.040 |
Why?
| | Leg | 1 | 2022 | 122 | 0.040 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2021 | 21 | 0.040 |
Why?
| | Cobalt | 1 | 2021 | 16 | 0.040 |
Why?
| | Antigen-Antibody Reactions | 1 | 2021 | 14 | 0.040 |
Why?
| | Back | 1 | 2021 | 5 | 0.040 |
Why?
| | Protein Structure, Quaternary | 1 | 2021 | 27 | 0.040 |
Why?
| | Immunoglobulin Variable Region | 1 | 2021 | 16 | 0.040 |
Why?
| | Fibrosis | 1 | 2022 | 198 | 0.040 |
Why?
| | Torso | 1 | 2021 | 15 | 0.040 |
Why?
| | Fracture Fixation, Internal | 1 | 2021 | 44 | 0.040 |
Why?
| | Immune Sera | 1 | 2021 | 15 | 0.040 |
Why?
| | HLA Antigens | 1 | 2021 | 55 | 0.040 |
Why?
| | APACHE | 1 | 2021 | 25 | 0.040 |
Why?
| | Organ Dysfunction Scores | 1 | 2021 | 20 | 0.040 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2021 | 7 | 0.040 |
Why?
| | Indoles | 1 | 1994 | 283 | 0.040 |
Why?
| | Genome, Viral | 1 | 2021 | 79 | 0.040 |
Why?
| | Linoleic Acid | 1 | 2021 | 16 | 0.040 |
Why?
| | Directed Molecular Evolution | 1 | 2020 | 2 | 0.040 |
Why?
| | Intestinal Perforation | 1 | 2021 | 24 | 0.040 |
Why?
| | Immunization, Secondary | 1 | 2021 | 26 | 0.040 |
Why?
| | Databases, Protein | 1 | 2021 | 29 | 0.040 |
Why?
| | Government | 1 | 2020 | 3 | 0.040 |
Why?
| | Virulence | 1 | 2021 | 160 | 0.040 |
Why?
| | Fluorescent Antibody Technique | 1 | 2021 | 110 | 0.040 |
Why?
| | Workplace | 1 | 2021 | 96 | 0.040 |
Why?
| | Public Health | 1 | 2003 | 224 | 0.040 |
Why?
| | Bone Transplantation | 1 | 2020 | 42 | 0.040 |
Why?
| | Femur Head | 1 | 2020 | 26 | 0.040 |
Why?
| | Psychological Theory | 1 | 2020 | 26 | 0.040 |
Why?
| | Cefazolin | 1 | 2020 | 11 | 0.040 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2021 | 40 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2024 | 1429 | 0.040 |
Why?
| | North America | 1 | 2020 | 75 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2021 | 96 | 0.040 |
Why?
| | Penicillins | 1 | 2020 | 29 | 0.040 |
Why?
| | Endothelial Cells | 1 | 2022 | 283 | 0.040 |
Why?
| | Infant, Low Birth Weight | 1 | 2021 | 77 | 0.040 |
Why?
| | Dependovirus | 1 | 2021 | 104 | 0.040 |
Why?
| | Salvage Therapy | 1 | 2021 | 137 | 0.040 |
Why?
| | Structure-Activity Relationship | 1 | 2021 | 399 | 0.040 |
Why?
| | Operating Rooms | 1 | 2020 | 27 | 0.040 |
Why?
| | Osteoblasts | 1 | 2023 | 478 | 0.040 |
Why?
| | Aftercare | 1 | 2020 | 67 | 0.040 |
Why?
| | Infection Control | 1 | 2020 | 46 | 0.040 |
Why?
| | Patella | 1 | 2019 | 11 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2020 | 91 | 0.040 |
Why?
| | Heel | 1 | 2019 | 7 | 0.040 |
Why?
| | Intestines | 1 | 2021 | 159 | 0.040 |
Why?
| | Shoes | 1 | 2019 | 15 | 0.040 |
Why?
| | Virus Replication | 1 | 2021 | 147 | 0.040 |
Why?
| | Sutures | 1 | 2019 | 36 | 0.040 |
Why?
| | Cross-Priming | 1 | 2019 | 2 | 0.040 |
Why?
| | Immunodominant Epitopes | 1 | 2019 | 9 | 0.040 |
Why?
| | Bone and Bones | 1 | 2023 | 492 | 0.040 |
Why?
| | Gestational Age | 1 | 2021 | 415 | 0.040 |
Why?
| | Time and Motion Studies | 1 | 2019 | 11 | 0.040 |
Why?
| | Sports Equipment | 1 | 2019 | 4 | 0.040 |
Why?
| | Disability Evaluation | 1 | 2019 | 92 | 0.040 |
Why?
| | Software | 1 | 2021 | 281 | 0.040 |
Why?
| | Computational Biology | 1 | 2021 | 209 | 0.040 |
Why?
| | Cloning, Molecular | 1 | 2019 | 181 | 0.040 |
Why?
| | Physical Examination | 1 | 2019 | 98 | 0.040 |
Why?
| | Body Weight | 1 | 2021 | 524 | 0.040 |
Why?
| | Telephone | 1 | 2019 | 70 | 0.040 |
Why?
| | Biopsy | 1 | 2021 | 594 | 0.040 |
Why?
| | Sequence Analysis, Protein | 1 | 2018 | 19 | 0.040 |
Why?
| | Pollination | 1 | 2018 | 2 | 0.040 |
Why?
| | Lymphocyte Activation | 1 | 2019 | 161 | 0.040 |
Why?
| | Sequence Alignment | 1 | 2018 | 121 | 0.040 |
Why?
| | Rabbits | 1 | 2019 | 370 | 0.040 |
Why?
| | Radiochemistry | 1 | 2018 | 2 | 0.040 |
Why?
| | Bombesin | 1 | 2018 | 3 | 0.040 |
Why?
| | Quality Assurance, Health Care | 1 | 2019 | 147 | 0.040 |
Why?
| | Electronic Health Records | 1 | 2021 | 274 | 0.040 |
Why?
| | Cerebrovascular Circulation | 1 | 2019 | 126 | 0.040 |
Why?
| | Drug Stability | 1 | 2018 | 38 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2020 | 288 | 0.030 |
Why?
| | Tissue Distribution | 1 | 2018 | 175 | 0.030 |
Why?
| | Isotope Labeling | 1 | 2018 | 59 | 0.030 |
Why?
| | Prospective Studies | 2 | 2002 | 2433 | 0.030 |
Why?
| | Morphine | 1 | 2018 | 104 | 0.030 |
Why?
| | Linear Models | 1 | 2018 | 288 | 0.030 |
Why?
| | Molecular Weight | 1 | 2017 | 78 | 0.030 |
Why?
| | Ultracentrifugation | 1 | 2017 | 10 | 0.030 |
Why?
| | Surface Plasmon Resonance | 1 | 2017 | 19 | 0.030 |
Why?
| | Fluorescence Resonance Energy Transfer | 1 | 2017 | 17 | 0.030 |
Why?
| | Amino Acid Motifs | 1 | 2017 | 59 | 0.030 |
Why?
| | Protein Folding | 1 | 2017 | 60 | 0.030 |
Why?
| | Universities | 1 | 2018 | 174 | 0.030 |
Why?
| | Solubility | 1 | 2017 | 81 | 0.030 |
Why?
| | Macadamia | 1 | 2016 | 1 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2017 | 127 | 0.030 |
Why?
| | Attitude to Health | 1 | 2018 | 191 | 0.030 |
Why?
| | Oxygen | 1 | 2019 | 332 | 0.030 |
Why?
| | Extracellular Matrix | 1 | 2017 | 116 | 0.030 |
Why?
| | Humidity | 1 | 2016 | 4 | 0.030 |
Why?
| | Volatilization | 1 | 2016 | 5 | 0.030 |
Why?
| | Diffusion | 1 | 2016 | 12 | 0.030 |
Why?
| | Probability | 1 | 2016 | 171 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2021 | 1483 | 0.030 |
Why?
| | Protein Array Analysis | 1 | 2015 | 24 | 0.030 |
Why?
| | Genes, Bacterial | 1 | 2015 | 51 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2019 | 1202 | 0.030 |
Why?
| | Students | 1 | 2018 | 230 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2015 | 114 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2019 | 1013 | 0.030 |
Why?
| | Hazardous Substances | 1 | 2015 | 17 | 0.030 |
Why?
| | Emergency Service, Hospital | 1 | 2019 | 521 | 0.030 |
Why?
| | Temperature | 1 | 2016 | 166 | 0.030 |
Why?
| | Equipment Design | 1 | 2016 | 287 | 0.030 |
Why?
| | Corrosion | 1 | 2014 | 4 | 0.030 |
Why?
| | Safety | 1 | 2015 | 78 | 0.030 |
Why?
| | Urban Population | 1 | 2015 | 161 | 0.030 |
Why?
| | Data Collection | 1 | 2016 | 285 | 0.030 |
Why?
| | Ions | 1 | 2014 | 31 | 0.030 |
Why?
| | Sf9 Cells | 1 | 2014 | 2 | 0.030 |
Why?
| | Metals | 1 | 2014 | 37 | 0.030 |
Why?
| | Disease Progression | 1 | 2017 | 870 | 0.030 |
Why?
| | Smoking Cessation | 1 | 2017 | 316 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2021 | 2871 | 0.030 |
Why?
| | Escherichia coli | 1 | 2014 | 182 | 0.020 |
Why?
| | Health Personnel | 1 | 2016 | 255 | 0.020 |
Why?
| | Twins, Monozygotic | 1 | 1992 | 15 | 0.020 |
Why?
| | Thrombophlebitis | 1 | 1992 | 17 | 0.020 |
Why?
| | Arthritis, Rheumatoid | 1 | 1992 | 114 | 0.020 |
Why?
| | Vena Cava Filters | 1 | 1992 | 30 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 1991 | 130 | 0.020 |
Why?
| | Prognosis | 1 | 1996 | 2100 | 0.020 |
Why?
| | Pelvic Bones | 1 | 1990 | 13 | 0.020 |
Why?
| | Dextrans | 1 | 1990 | 16 | 0.020 |
Why?
| | Thromboembolism | 1 | 1990 | 48 | 0.020 |
Why?
| | Leg Injuries | 1 | 1989 | 10 | 0.020 |
Why?
| | Irritants | 1 | 2008 | 1 | 0.020 |
Why?
| | Ergosterol | 1 | 2008 | 10 | 0.020 |
Why?
| | Mycotoxins | 1 | 2008 | 11 | 0.020 |
Why?
| | Glucans | 1 | 2008 | 10 | 0.020 |
Why?
| | Surgical Flaps | 1 | 1989 | 111 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 1507 | 0.020 |
Why?
| | Fetal Resorption | 1 | 1994 | 2 | 0.010 |
Why?
| | Pineal Gland | 1 | 1994 | 9 | 0.010 |
Why?
| | Fetal Death | 1 | 1994 | 25 | 0.010 |
Why?
| | Organ Culture Techniques | 1 | 1994 | 47 | 0.010 |
Why?
| | Organ Size | 1 | 1994 | 226 | 0.010 |
Why?
| | Fetus | 1 | 1994 | 191 | 0.010 |
Why?
| | Phlebography | 2 | 1992 | 54 | 0.010 |
Why?
| | Pregnancy | 1 | 1994 | 2642 | 0.010 |
Why?
| | Prothrombin Time | 1 | 1992 | 18 | 0.010 |
Why?
| | Drug Monitoring | 1 | 1992 | 81 | 0.010 |
Why?
| | Warfarin | 1 | 1992 | 81 | 0.010 |
Why?
| | Urogenital System | 1 | 1990 | 3 | 0.010 |
Why?
| | Multiple Trauma | 1 | 1990 | 30 | 0.010 |
Why?
| | Femoral Neck Fractures | 1 | 1990 | 7 | 0.010 |
Why?
| | Injury Severity Score | 1 | 1990 | 165 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 1992 | 641 | 0.000 |
Why?
| | Prevalence | 1 | 1990 | 1016 | 0.000 |
Why?
|
|
Barnes's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
|